HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer-Reference-Cited by-同舟云学术

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

Published:2018-07-30 Issue:3 Volume:37 Page:441-451
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Canonici Alexandra,Ivers Laura,Conlon Neil T.,Pedersen Kasper,Gaynor Nicola,Browne Brigid C.,O’Brien Neil A.,Gullo Giuseppe,Collins Denis M.,O’Donovan Norma^ORCID,Crown John

Funder

Health Research Board (IE)

Irish Research Council for Science, Engineering and Technology

Science Foundation Ireland (IE)

Irish Cancer Society

Cancer Clinical Research Trust

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-018-0649-y.pdf

Reference32 articles.

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. https://doi.org/10.1056/NEJM200103153441101

2. Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J (2012) Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 23:2204–2205. https://doi.org/10.1093/annonc/mds221

3. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724–734. https://doi.org/10.1056/NEJMoa1413513

4. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S (2008) Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13:620–630. https://doi.org/10.1634/theoncologist.2008-0001

5. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32. https://doi.org/10.1016/S1470-2045(11)70336-9

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo;Translational Oncology;2024-11

2. Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors;Chinese Journal of Cancer Research;2024

3. Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2;International Journal of Biological Macromolecules;2024-01

4. Privileged Scaffolds in Drug Discovery against Human Epidermal Growth Factor Receptor 2 for Cancer Treatment;Current Pharmaceutical Design;2023-12

5. Molecular structure, spectral analysis and chemical activity of sabizabulin: A computational study;Journal of Molecular Graphics and Modelling;2023-12